Medicalgorithmics’ new cloud-based arrhythmia diagnostic platform, DeepRhythm Platform (DRP), has been registered by Health Canada for use in the country. This approval allows for the commercial implementation of the new solution for clients in the Canadian market, one of Medicalgorithmics’ key markets where it offers ECG data analysis services. The DRP platform is integrated with the latest generation of proprietary artificial intelligence algorithms, DRAI, which was registered in Canada earlier this month.
DeepRhythm Platform (DRP) is a cloud platform that uses the latest technologies to ensure high performance, scalability, and security in heart arrhythmia diagnostics. Thanks to the integration with the new generation of DeepRhythmAI (DRAI) artificial intelligence algorithms, which are best in class, DRP offers high diagnostic accuracy and flexibility, allowing the analysis of data from various types of ECG recorders used globally for arrhythmia diagnostics. The DRP platform, along with the new generation of DRAI AI algorithms, is one of two strategic research and development projects being undertaken by Medicalgorithmics. The approval from Health Canada enables the commercial rollout of the new solution to clients in the Canadian market.
“We are consistently executing our development plan and have reached a significant milestone for us. The decision by Health Canada allows us to strengthen our position in the market, which is one of our most important markets, where we have been offering our ECG data analysis products for many years. The registration of DRP, integrated with the already approved DRAI in the Canadian market, increases our technological advantage and will allow us to expand the scope of our services for our partner in this market,” emphasizes Przemysław Tadla, a board member and CTO at Medicalgorithmics.
The DRP platform, combined with the DRAI algorithm set, represents a new generation of Medicalgorithmics’ products, ensuring high performance, scalability, and security in arrhythmia diagnostics. In the first half of this year, the company completed the regulatory approval process for both solutions in strategic markets—the U.S. (FDA) and Europe (CE). As a result, Medicalgorithmics now offers its clients in the U.S. and Europe the DRAI algorithms as a standalone product or in combination with the DRP cloud platform, which provides physicians and ECG technicians with access to analysis results. Both solutions have already been successfully commercialized with initial clients.
The Health Canada decision places the company’s product offering among the global leaders, opens up new business opportunities, and enhances its competitive and technological advantage in the arrhythmia diagnostics market. It will enable Medicalgorithmics’ Canadian partner to use the company’s latest technology, strengthening Medicalgorithmics’ position and potentially accelerating revenue growth and the number of patients examined in Canada. As confirmed by the independent scientific study DRAI MARTINI, artificial intelligence makes 14 times fewer errors than humans in confirming critical cases of heart arrhythmias based on ECG data analysis. The study involved more than 50 cardiologists from Europe and the U.S., and its results were presented at the ESC Congress 2024, the largest cardiology conference in Europe.
Since 2018, Medicalgorithmics’ strategic partner in the Canadian market has been m-Health Solutions, a company specializing in cardiology diagnostics and remote heart monitoring. In mid-2023, the parties expanded their cooperation: the Polish company delivered 300 fourth-generation PocketECG heart monitoring devices to Canada and integrated the partner’s other devices with its own software and cardiological diagnostic algorithms.